

Press release

30.09.2021: Life Science Pitch Day in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim and IZB

Biotech start-ups or project teams can apply until September 10, 2021

Martinsried near Munich, July 5, 2021 - On September 30, 2021, the IZB, in cooperation with High-Tech Gründerfonds, Bayer AG and Boehringer Ingelheim, will hold the Life Science Pitch Day for the sixth time. This year, the event has so far been planned as an online event. Biotech start-ups and project teams have the opportunity to apply at lifescience-pitchday@htgf.de until September 10, 2021. Ten teams will be selected to present their innovations to life science investors and decision makers and receive qualified feedback. "In recent years, we have seen again and again that researchers and VCs get to know each other at the Life Science Pitch Day and subsequently realize successful financing," said Dr. Peter Hanns Zobel, Managing Director of the Biotechnology Innovation and Start-up Center (IZB). In addition to the partners, the following venture capital companies will participate in the event: Bayern Kapital, BioMed Partners, Coparion, Forbion, Kurma Partners, LSP, Occident, Sventure, TVM Capital, Vesalius Bio Capital and Wellington Partners.

At the beginning of the event, Dr. Peter Hanns Zobel will give the welcome speech and provide an insight into the incubator. In addition, Prof. Dr. Stefan Jaroch, Head External Innovation Technologies, R&D Bayer AG, will present the cooperation opportunities with the pharmaceutical company. Dr. Caroline Fichtner and Dr. Martin Pfister, principals of High-Tech Gründerfonds, will also present their company and provide the start-ups with qualified Feedback based on their many years of experience in the venture capital industry. In two presentation rounds, the ten to twelve project teams will present their research. Participation in the Life Science Pitch Day is free of charge.

Press photo: Munich Life Science Pitch Day 2019 and capture:



Investors at the 5th Munich Life Science Pitch Day 2019 (f.l.t.r.): Dr. Joachim Vogt, abbVie Inc.; Fis emri, Saverna Therapeutics.; Andreas Huber, Bayern Kapital; Dr. Holger Reithinger, Forbion Capital Partners; Annegret de Baey-Diepolder, Seventure Partners; Dr. Marianne Mertens, Wellington Partners Advisory AG; Dr. Joachim Rothe, Life Sciences Partners; Thomas Möller, BioMedPartners AG; Laurent Jacqueroud, Kurma Partners SA; Dr. Ioannis Sapountzis, Boehringer Ingelheim; Dr. Bernd Goergen, HTGF; Christoph Kocher, gimv; Daniel Parera, TVM Life Science Management GmbH; Dr. Marie Asano, HTGF; Dr. Lena Krzyzak, HTGF; Dr. Daniel Dillinger, Redalpine Venture Partners AG; Dr. Benedikt Luhmann, VI Partners AG; Dédric Barra, Occident Group AG; Dr. Peter Neubeck, Kurma Partners SA

About Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich

The development company IZB mbH, founded in 1995, is the operating company of the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently located on 26,000 m² of land. Here, work focuses on the development of drugs against the most serious diseases, such as cancer, Alzheimer's and various autoimmune diseases. A key criterion for the success of the IZBs is their close proximity to top-level research at both the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt Chemistry College, the two kindergartens Bio Kids and Bio Kids2, as well as the two restaurants SEVEN AND MORE and Café Freshmaker are also location factors that are highly appreciated by the company founders. Successful companies that have emerged from the IZB include Medigene AG, MorphoSys AG, Micromet GmbH (today Amgen AG), Octopharma GmbH, Corimmun (today Janssen-Cilag), Rigontec GmbH (today MSD), ibidi GmbH, Coriolis GmbH and Immunic Therapeutics. More information at www.izb-online.de

Press contact and image requests:

Susanne Simon, Head of Public Relations

Fördergesellschaft IZB mbH, Am Klopferspitz 19, D-82152 Planegg Martinsried

Phone: +49 (0)89/55 279 48-17,

E-mail: simon@izb-online.de; Website: www.izb-online.de